首页AutophagyRas
Ras
T6163 Salirasib Salirasib(Ki=2.6 μM), an effective competitive prenylated protein methyltransferase (PPMTase) inhibitor, inhibits Ras methylation with potential antineoplastic activity.
T6302 Lonafarnib Lonafarnib is an orally bioavailable FPTase inhibitor for H-ras, K-ras-4B, and N-ras (IC50: 1.9/5.2/2.8 nM).
T4619 ML098 ML-098 is an activator of the GTP-binding protein Rab7 (EC50: 77.6 nM).
T5379 Antineoplaston A10 Antineoplaston A10 is a naturally occurring substance and the first antineoplaston in the human body to be chemically identified. It displayed anti-proliferative action inhibiting
T7131 Antineoplaston A10 Antineoplaston A 10 is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.
T7328 AMG-510 AMG-510 is a potent KRAS G12C covalent inhibitor, treatment with AMG 510 led to the regression of KRASG12C tumours and improved the anti-tumour efficacy of chemotherapy and targete
T7326 6H05 6H05 is a selective, and allosteric oncogenic mutant K-Ras(G12C) inhibitor.
T7609 ARS-1620 ARS-1620 is a covalent inhibitor of K-RASG12C.
T7558 CID-1067700 CID-1067700 is one of the first identified competitive inhibitors of nucleotide binding by Ras-related GTPases(Rab7 with a Ki of 13 nM).
T8006 Oncrasin 1 Oncrasin 1 is a potent inhibitor of anticancer that kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations
T8369 MRTX849 MRTX849 is a potent, selective, and covalent KRASG12C inhibitor with potential antineoplastic activity.selectively modifies mutant cysteine 12 in GDP-bound KRASG12C, and inhibits K
T13844 PROTAC K-Ras Degrader-1 PROTAC K-Ras Degrader-1 is potent degrader of K-Ras based PROTAC.
T10375 ARS-1323 ARS-1323 (the racemate of ARS-1620) is a mutant K-ras G12C inhibitor extracted from patent WO 2015054572 A1.
T10374 ARS-1323-alkyne ARS-1323-alkyne is a switch-II pocket (S-IIP) inhibitor and a conformational specific chemical reporter of KRASG12C nucleotide state in living cells.
T10376 ARS-1630 ARS-1630 is a mutant K-ras G12C inhibitor extracted from patent WO 2015054572 A1. It is a less active enantiomer of ARS-1620.
T12979 BI-3406 BI-3406 is an orally active, highly potent and selective between KRAS and Son of Sevenless 1 (SOS1) interaction inhibitor(IC50 of 6 nM),with anticancer activity.
T10533 BI-2852 BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) with nanomolar affinity. BI-2852 is leading to inhibition of downstream signaling and an antiproliferative eff
T11744 KB-5246 KB-5246, displays antibacterial activities.is a tetracyclic quinolone.
T16023 MC 976 MC 976 is a derivative of Vitamin D3.
T11767 KRAS G12C inhibitor 13 KRAS G12C inhibitor 13 is a KRAS G12C inhibitor .
T11768 KRAS G12C inhibitor 14 KRAS G12C inhibitor 14 is a potent KRAS G12C inhibitor . 
T11769 KRAS G12C inhibitor 15 KRAS G12C inhibitor 15 is a potent KRAS G12C inhibitor .
T11770 KRAS G12C inhibitor 16 KRAS G12C inhibitor 16 is a potent KRAS G12C inhibitor.
T11771 KRAS G12C inhibitor 17 KRAS G12C inhibitor 17 is a potent KRAS G12C inhibitor. 
T11773 KRAS inhibitor-6 KRAS inhibitor-6 is a potent KRAS G12C inhibitor.
T11774 KRAS inhibitor-7 KRAS inhibitor-7 is a potent KRAS G12C inhibitor.
T11775 KRAS inhibitor-8 KRAS inhibitor-8 is a potent KRAS G12C inhibitor.
T11776 KRas G12C inhibitor 1 KRas G12C inhibitor 1 is a compound that inhibits KRas G12C.
T11777 KRas G12C inhibitor 2 KRas G12C inhibitor 2 is a compound that inhibits KRas G12C.
T11778 KRas G12C inhibitor 3 KRas G12C inhibitor 3 is a compound that inhibits KRas G12C.
T11779 KRas G12C inhibitor 4 KRas G12C inhibitor 4 is a compound that inhibits KRas G12C.
T11780 KRAS G12C inhibitor 5 KRAS G12C inhibitor 5 is a KRas G12C inhibitor.
T8684 AMG-510 AMG-510 is a selective and orally bioavailable KRAS G12C covalent inhibitor.
  • 关注公众号
    - 超值特惠
    - 客户福利
    - 业界动态
    - 实用攻略
陶素的所有产品和服务仅用于科学研究,我们不为任何其他用途提供产品和服务(也不为任何个人提供产品和服务)。